Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Technical Presentation (August 2021)

23 slides from Dicerna Pharmaceuticals's technical presentation, Aug 6, 2021

  1. Slide 1: Topline Data Presentation: Nedosiran for Primary Hyperoxaluria Type 1 and Type 2

    Topline Data Presentation Investigation of Nedosiran for the Treatment of Primary Hyperoxaluria Type 1 and Type 2 August 5, 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi

  3. Slide 3: Speakers and Agenda

    Douglas M. Fambrough, Ph.D. President and Chief Executive Officer Introduction GalXC RNAi Technology Pipeline Rob Ciappenelli Chief Commercial Officer Disease and Patient Journey Shreeram Aradhye, M.D. Executive Vice President, Chief Medical Officer PHYOX2 Data Trial design Demographics Efficacy End

  4. Slide 4: Dicerna's RNAi Platform Offering Compelling Pharmacological Properties

    • Sequence-specificity to silence only the targeted gene in the delivery tissues • Long duration of action – weeks to months – enables convenient dosing regimens • Off-target activity is generally not observed • Ability to address previously “undruggable” target classes Dicerna’s & RNAi Platform Off

  5. Slide 5: Core and Collaborative Development-Stage Programs

    With 20+ discovery-stage programs in multiple tissues Core and Collaborative Development-Stage Programs Fifteen Programs Have Entered Development, Many More Are in Discovery Stage TARGET INDICATION COMPOUND (GENE TARGET) PRECLINICAL PHASE 1 PHASE 2 PHASE 3 DICERNA PRODUCT RIGHTS PARTNER Primary Hype

  6. Slide 6: Disease and Patient Journey

    Disease and Patient Journey Chief Commercial Officer Rob Ciappenelli

  7. Slide 7: The Primary Hyperoxalurias

    The Primary Hyperoxalurias • A family of three closely-related ultra-rare genetic diseases ‒ PH type 1 ‒ PH type 2 ‒ PH type 3 • All subtypes of PH are associated with high urinary oxalate levels, resulting in potentially severe health and quality-of-life consequences ‒ Frequent kidney stones ‒ Prog

  8. Slide 8: Patient Journey Demonstrates Challenges in PH Awareness and Diagnosis

    Patient Journey Demonstrates Challenges in PH Awareness, Disease Education and Diagnosis Majority of PH Patients Across Subtypes Remain Undiagnosed 8 Emergency Department Nephrologist Pt/Caregiver Renal Impairment PH Diagnosis Genetic Testing 24hr UoxKidney Stones Heterogenous Symptoms (e.g., Pain,

  9. Slide 9: PHYOX2 Data

    PHYOX2 Data Executive Vice President, Chief Medical Officer Shreeram Aradhye, M.D.

  10. Slide 10: Primary Hyperoxaluria Disease Biology

    Primary Hyperoxaluria Disease Biology A Family of Ultra-Rare, Life-Threatening Genetic Disorders Resulting in Renal Complications 10 PEROXISOME Oxalate GO Primary hyperoxaluria 1 Glycolate Glyoxylate Primary hyperoxaluria 2 & 3 Glycine LDH nedosiran AGT HEPATOCYTE GRHPR Glyoxylate Glycolate MITOCHON

  11. Slide 11: Study Design

    Study Design 11 Key Eligibility Criteria  Adults and children (>6 yo) Genetically confirmed PH1/PH2 (AGXT/GRHPR mutations)  eGFR >30 ml/min/1.73m2  Urinary Oxalate (Uox) excretion >0.7 mmol/24hr/1.73m2 2:1 Randomization Nedosiran Placebo Intent to Treat (ITT) Population 6-Month Double-Blind Treat

  12. Slide 12: Subject Disposition

    Subject Disposition All Screened Participants 12 57 participants were screened 22 were not enrolled • Most common reasons for screen failure were Uox <0.7 mmol/24hr or baseline urine creatinine variability >20% 35 participants enrolled and randomized 23 participants assigned to receive nedosiran 12

  13. Slide 13: Baseline Characteristics

    Baseline Characteristics 13 Category or Statistic Nedosiran (n = 23) Placebo (n = 12) Mean Age (years) / 6-11 (years) 23.7 / 3 (13.0%) 23.6 / 2 (16.7%) PH Type 1 / 2 18 (78.3%)/5 (21.7%) 11 (91.7%)/ 1 (8.3%) White 15 (65.2%) 10 (83.3%) Weight (kg), Mean(SD) 64.93 (19.3) 72.75 (27.3) Baseline eGFR (m

  14. Slide 14: PHYOX2 Met Primary Endpoint Achieving a Significant Reduction in Uox

    PHYOX2 Met Primary Endpoint Achieving a Significant Reduction in Uox Mean AUC24-hour Uox (Day 90 to Day 180) 14 Standardized AUC24-hour Uox from Day 90 to Day 180** Nedosiran (n=22) Placebo (n=12) n 22 12 LS Mean (SE) 3507.4 (788.49) -1664.4 (1189.96) 95% CI for LS Mean (1961.7, 5053.1) (-3997.2, 66

  15. Slide 15: Significant Reduction in 24h Uox in PH1, Not PH2

    Significant Reduction From Baseline in 24h Uox Between Day 90-180 in PH1, But Not PH2 15 * Overall and PH1 data based on restricted maximum likelihood based MMRM approach ** PH2 analysis based on observed data given small n Average % Change From Baseline in 24-Hr Uox Between Day 90 to 180 -51% -59%

  16. Slide 16: PHYOX2 Met Key Secondary Endpoint

    0 10 20 30 40 50 60 70 Nedosiran (n=22) Placebo (n = 12) 0% 50% PHYOX2 Met Key Secondary Endpoint: Proportion of Participants Reaching Normalization/Near-Normalization ≥2 Consecutive Visits ≥D90 16 *24-hour Uox values are considered normalized if the value <0.46 mmol/24 hours (upper limit of assay n

  17. Slide 17: Positive Responder Analysis

    0 10 20 30 40 50 60 70 Nedosiran (n=22) Placebo (n = 12) 0% 59% Positive Responder Analysis: Proportion of Participants Meeting Normalization/Near- Normalization Criteria OR ≥70% Reduction in Uox on ≥2 Consecutive Visits ≥D90 17 24-hour Uox values are considered normalized if the value <0.46 mmol/24

  18. Slide 18: Additional Subgroup Analysis in PH1 Participants

    Additional Subgroup Analysis: Normalization/Near-Normalization and Uox Changes in PH1 Participants Nedosiran (n = 17) Placebo (n = 11) p-value*** Normalized* (at Day 180) 43.8% ** 0% ** 0.0174 Near-Normalized + Normalized* (at Day 180) 81.3%** 0%** <0.0001 Normalized* (≥1 visit) 65% 9% 0.0047 Maxima

  19. Slide 19: Treatment-Emergent Adverse Events and Laboratory Findings

    Treatment-Emergent Adverse Events and Laboratory Findings • Two discontinuations, both due to SAEs (1 nedosiran and 1 placebo) • Three total SAEs were reported (1 nedosiran and 2 placebo): ‒ One participant with fluctuating tachycardia on nedosiran (considered not to be related to study drug by two

  20. Slide 20: PHYOX2 Summary of Top-Line Data

    • Nedosiran achieved the primary and key secondary endpoints with a statistically significant reduction in Uox • Robust Uox reduction seen in the PH1 subpopulation • PH2 results inconsistent with prior experience • Nedosiran was generally well tolerated, and its AE profile was consistent with previo

  21. Slide 21: Summary and Conclusions

    Doug Fambrough, Ph.D. President and Chief Executive Officer Summary and Conclusions

  22. Slide 22: Summary and Conclusions

    Summary and Conclusions • Nedosiran decisively hit the primary and key secondary endpoints in PHYOX2 • Nedosiran showed an AE profile similar to previously reported PHYOX trial results • The success of nedosiran in PH1 validates the GalXC technology at the foundation of our proprietary and partnered

  23. Slide 23: Dicerna.com

Dicerna Pharmaceuticals — Technical Presentation (August 2021) on 6ix